2 min read
South Africa’s pharmaceutical market is becoming more attractive for global manufacturers, and the country’s regulator is working hard to remove long-standing approval bottlenecks.
The South African Health Products Regulatory Authority (SAHPRA) has made major progress in reducing Regulatory backlogs while introducing faster review timelines and more efficient approval pathways.
For pharmaceutical companies entering South Africa, this could mean faster market access, but only for companies prepared to meet evolving Regulatory expectations.
Why SAHPRA’s Backlog Reduction Matters
For years, SAHPRA struggled with a large volume of pending applications inherited from its predecessor, the Medicines Control Council.
At one point, the regulator faced a backlog of nearly 16,000 applications, including:
- New registrations
- Variations
- Duplicates
- Multiple dosage forms
Many applications date back several years, creating major delays for manufacturers trying to enter the South African market.
To solve this, SAHPRA introduced a structured backlog clearance strategy focused on:
- Prioritizing high-need medicines
- Eliminating outdated applications
- Improving operational efficiency
- Increasing transparency
- Implementing digital systems
These efforts significantly improved approval efficiency.
Faster Review Timelines Are Reshaping Approvals
According to recent industry updates, SAHPRA is maintaining clearer review timelines across product categories:
- New Chemical Entities: 360 working days
- Generics (with clinical data): 360 working days
- Generics (without clinical data): 250 working days
- Biologicals: 360 working days
- Biosimilars: 360 working days
For global pharma companies, this brings greater predictability to launch planning.
Growing Focus on Reliance-Based Reviews
One of SAHPRA’s biggest shifts is its increased use of reliance pathways, where the regulator leverages approvals and assessments from trusted global agencies.
This helps reduce duplicate evaluations while maintaining product safety standards.
The reliance review pathway is helping shorten approval timelines significantly compared to full reviews. Research shows abridged reviews reduced approval timelines for certain products by over 100 days.
This is especially beneficial for companies with products already approved by Reference Regulatory Authorities (RRAs) recognized under South African Health Products Regulatory Authority reliance guidelines, such as:
- Therapeutic Goods Administration
- Swissmedic
- Pharmaceuticals and Medical Devices Agency
- Health Sciences Authority
Digital Transformation Is Improving Efficiency
SAHPRA is also investing in digital modernization to reduce administrative delays.
Its strategic plan highlights:
- Application tracking improvements
- Digital submissions
- Faster communication processes
- Reduced manual inefficiencies
For companies still using outdated submission processes, adapting quickly will be important.
What This Means for Global Pharma Companies
These reforms create major opportunities for:
- Generic manufacturers
- Innovator pharma companies
- Biosimilar developers
- Veterinary product companies
- Companies expanding into Africa
Benefits include:
- Faster approvals
- Better planning predictability
- Improved market access
- Reduced backlog-related uncertainty
But companies still need strong submission strategies to avoid delays.
Why Regulatory Support Still Matters
Even with faster approvals, Regulatory complexity remains.
Companies may still face challenges related to:
- Dossier preparation
- Variations
- Local compliance requirements
- Submission formatting
- Regulatory communication
Working with experienced Regulatory partners can help companies move faster while reducing compliance risks.
Planning to expand into South Africa? Talk to Freyr experts today.
